Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Key Highlights
- ➤EVX-01 phase 2 immune data will be presented orally and by poster at SITC 2026
- ➤EVX-01 phase 2 trial combines personalized vaccine with pembrolizumab in advanced melanoma
- ➤Two-year ORR reached 75%, with 12 of 16 patients showing objective responses
- ➤Four patients achieved complete responses in the EVX-01 phase 2 trial
- ➤92% of patients continued responding at two-year follow-up, with no relapses observed
Expert Statements
Mads Lausen, Senior Scientist at Evaxion
“EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma”
* New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation * New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026 COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.
The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC meeting.
Get started
Create a free account to read the full story.